Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

CAS  PubMed  Google Scholar 

Ychou M, Boige V, Pignon J-P, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.

CAS  PubMed  Google Scholar 

Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.

PubMed  Google Scholar 

Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: Interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304.

CAS  PubMed  PubMed Central  Google Scholar 

Bang Y-J, Kim Y-W, Yang H-K, Chung HC, Park Y-K, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.

CAS  PubMed  Google Scholar 

Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, et al. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study. Gastric Cancer. 2023;26:1063–8.

CAS  PubMed  PubMed Central  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

CAS  PubMed  Google Scholar 

Kang Y-K, Yook JH, Park Y-K, Lee JS, Kim Y-W, Kim JY, et al. PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903–13.

CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol [Internet]. 2025;26(3):312–9 [cited 12 Feb 2025]. http://www.thelancet.com/article/S1470204524006764/abstract.

Drake JA, Stiles ZE, Tsao MW, Deneve JL, Glazer ES, Yakoub D, et al. Analysis of the survival impact of postoperative chemotherapy after preoperative chemotherapy and resection for gastric cancer. Ann Surg Oncol. 2021;28:1417–27.

PubMed  Google Scholar 

Rahman S, Thomas B, Maynard N, Park MH, Wahedally M, Trudgill N, et al. Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery. Br J Surg. 2022;109:227–36.

PubMed  Google Scholar 

Deng L, Groman A, Jiang C, Perimbeti S, Gabriel E, Kukar M, et al. Association of preoperative chemosensitivity with postoperative survival in patients with resected gastric adenocarcinoma. JAMA Netw Open. 2021;4: e2135340.

PubMed  PubMed Central  Google Scholar 

SPACE-FLOT Investigators. Pathological response guides adjuvant 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in surgically resected gastro-oesophageal cancer (SPACE-FLOT): international cohort study. Br J Surg. 2025;112:znaf056.

Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathol Correlat Cancer. 1994;73:2680–6.

CAS  Google Scholar 

Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncol. 2017;18:357–70.

CAS  PubMed  PubMed Central  Google Scholar 

Capovilla G, Pierobon ES, Moletta L, Scarton A, Sciuto ME, Tagkalos E, et al. Prognostic value of tumor regression grade after chemotherapy versus chemoradiotherapy in patients undergoing neoadjuvant treatment for locally advanced esophageal adenocarcinoma. Ann Surg Oncol. 2025;1–10.

Heckl SM, Behrens H-M, Ebert U, Ulase D, Richter F, Becker T, et al. Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world. Gastric Cancer. 2025;1–11.

Saliba G, Detlefsen S, Carneiro F, Conner J, Dorer R, Fléjou JF, et al. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey. Hum Pathol. 2021;108:60–7.

CAS  PubMed  Google Scholar 

Ramos MFKP, de Castria TB, Pereira MA, Dias AR, Antonacio FF, Zilberstein B, et al. Return to intended oncologic treatment (RIOT) in resected gastric cancer patients. J Gastrointest Surg. 2020;24:19–27.

PubMed  Google Scholar 

Garcia-Nebreda M, Zorrilla-Vaca A, Ripollés-Melchor J, Abad-Motos A, Alvaro Cifuentes E, Abad-Gurumeta A, et al. Early return to intended oncologic therapy after implementation of an enhanced recovery after surgery pathway for gastric cancer surgery. Langenbecks Arch Surg. 2022;407:2293–300.

PubMed  Google Scholar 

Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1249–60.

CAS  PubMed  PubMed Central  Google Scholar 

Lin J-X, Tang Y-H, Lin G-J, Ma Y-B, Desiderio J, Li P, et al. Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy. JAMA Netw Open. 2022;5: e225557.

PubMed  PubMed Central  Google Scholar 

Ballhausen A, Bartels P, Iacovella I, Hoegner A, Lorusso A, Bichev D, et al. Impact of postoperative chemotherapy in patients with gastric/gastroesophageal adenocarcinoma treated with perioperative chemotherapy. Curr Oncol. 2022;29:1983–96.

PubMed  PubMed Central  Google Scholar 

Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, et al. Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study. Ann Oncol [Internet]. 2024;36(2):197–207 [cited 14 Nov 2024]. http://www.annalsofoncology.org/article/S0923753424049068/abstract.

Mirza A, Pritchard S, Welch I. The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas. Int J Surg Oncol. 2013;2013: 781742.

CAS  PubMed  PubMed Central  Google Scholar 

Luc G, Gersen-Cherdieu H, Degrandi O, Terrebonne E, Chiche L, Collet D. Impact of postoperative chemotherapy in patients with locally advanced gastroesophageal adenocarcinoma treated with perioperative chemotherapy strategy. Am J Surg. 2015;210:15–23.

PubMed  Google Scholar 

Lichthardt S, Kerscher A, Dietz UA, Jurowich C, Kunzmann V, von Rahden BHA, et al. Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer. BMC Cancer. 2016;16:650.

PubMed  PubMed Central  Google Scholar 

Karagkounis G, Squires MH 3rd, Melis M, Poultsides GA, Worhunsky D, Jin LX, et al. Predictors and prognostic implications of perioperative chemotherapy completion in gastric cancer. J Gastrointest Surg. 2017;21:1984–92.

PubMed  Google Scholar 

van Putten M, Lemmens VEPP, van Laarhoven HWM, Pruijt HFM, Nieuwenhuijzen GAP, Verhoeven RHA. Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival. Eur J Surg Oncol. 2019;45:1926–33.

PubMed  Google Scholar 

Coimbra FJF, de Jesus VHF, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, et al. Impact of ypT, ypN, and adjuvant therapy on survival in gastric cancer patients treated with perioperative chemotherapy and radical surgery. Ann Surg Oncol. 2019;26:3618–26.

PubMed  Google Scholar 

Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AFC, Lampis A, et al. Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. J Clin Oncol. 2016;34:2721–7.

CAS  PubMed  PubMed Central  Google Scholar 

Huffman BM, Aushev VN, Budde GL, Chao J, Dayyani F, Hanna D, et al. Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers. JCO Precis Oncol. 2022;6: e2200420.

PubMed  PubMed Central  Google Scholar 

Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392:323–35.

PubMed  Google Scholar 

Kubo Y, Tanaka K, Yamasaki M, Yamashita K, Makino T, Saito T, et al. Influences of the Charlson Comorbidity Index and nutrition status on prognosis after esophageal cancer surgery. Ann Surg Oncol. 2021;28:7173–82.

PubMed  Google Scholar 

Kubo Y, Miyata H, Sugimura K, Shinno N, Asukai K, Hasegawa S, et al. Prognostic implication of postoperative weight loss after esophagectomy for esophageal squamous cell cancer. Ann Surg Oncol. 2021;28:184–93.

PubMed  Google Scholar 

Janjigian YY, Al-Batran S-E, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med [Internet]. 2025. https://doi.org/10.1056/nejmoa2503701

Clements HA, Underwood TJ, Petty RD. Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 2024;130:9–18.

PubMed  Google Scholar 

Clements HA, Dobrzhanskiy O, Yang J, Bausys A, Ferri LE, Ku GY, et al. 1428P Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: an international cohort study. Ann Oncol. 2024;35:S890.

Google Scholar 

Papaxoinis G, Kamposioras K, Weaver JMJ, Kordatou Z, Stamatopoulou S, Germetaki T, et al. The role of continuing perioperative chemotherapy post surgery in patients with esophageal or gastroesophageal junction adenocarcinoma: a multicenter cohort study. J Gastrointest Surg. 2019;23:1729–41.

PubMed  Google Scholar 

Cortes-Mejia NA, Lillemoe HA, Cata JP. Return to intended oncological therapy: state of the art and perspectives. Curr Oncol Rep. 2024;26:1420–30.

CAS  PubMed  Google Scholar 

Koo A, Mavani PT, Sok C, Goyal S, Concors S, Mason MC, et al. Effect of minimally invasive gastrectomy on return to intended oncologic therapy for gastric cancer. Ann Surg Oncol. 2025;32:230–9.

PubMed